Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program

INTRODUCTION: In October 2015, the Food and Drug Administration (FDA) instituted an update to the mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of hemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrelli, Eric P., Lee, Erica Y., Caffrey, Aisling R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213944/
https://www.ncbi.nlm.nih.gov/pubmed/32420002
http://dx.doi.org/10.9740/mhc.2020.05.070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213944/
https://www.ncbi.nlm.nih.gov/pubmed/32420002
http://dx.doi.org/10.9740/mhc.2020.05.070

Ejemplares similares